
    
      The primary objective of this study is to describe the effect of a single 30 mg/kg or 100
      mg/kg intravenous (IV) dose of Motavizumab compared to placebo on study drug levels and viral
      load as measured by cultivatable virus and real-time RT-PCR in the upper respiratory tract in
      previously healthy children â‰¤12 months of age who are hospitalized with lower respiratory
      tract illness.
    
  